Skip to content
VIRVir Biotechnology, Inc.

Earnings

When Vir Biotechnology, Inc. reports, what it reported each quarter, and how the stock took the results.

35 quarters. Mar 31, 2018 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Feb 22, after the close

Mon, Feb 22, 2027in 96 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 22 – Mar 3

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$64.07M
Revenue, change from a year earlier: Q3 2026 n/m, Q2 2026 +19,582.5%, Q1 2026 n/m, Q4 2025 +417.8%
Net income
-$42.92M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026-$188.00KNo Q3 2025 on file

Latest results

  1. Q3 2026Nov 4, 2026, after the closeThe release6.5%by the close of Nov 5
    Revenue
    -$188.00K
    N/M
    Net income
    -$96.25M
    N/M
    EPS
    -$0.57
    N/M
    The Company announced a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN ® dual-masked TCE development candidates targeting selected solid tumor-associated antigens.
  2. Q2 2026Aug 5, 2026, after the closeThe release3.7%by the close of Aug 6
    Revenue
    $238.95M
    +19,582.5%
    Net income
    $80.08M
    N/M
    EPS
    $0.47
    N/M
  3. Q1 2026May 6, 2026, after the closeThe release9.9%by the close of May 7
    Revenue
    -$29.00K
    N/M
    Net income
    -$125.70M
    N/M
    EPS
    -$0.85
    N/M
  4. Q4 2025Feb 23, 2026, after the closeThe release+28.0%by the close of Feb 24
    Revenue
    $64.07M
    +417.8%
    Net income
    -$42.92M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 4, 2026 · after-hoursNov 4, 202635 d10-Q-$188.00KN/M-$0.576.5%
Q2 2026Jun 30, 2026Aug 5, 2026 · after-hoursAug 5, 202636 d10-Q$238.95M+19,582.5%$0.473.7%
Q1 2026Mar 31, 2026May 6, 2026 · after-hoursMay 7, 202637 d10-Q-$29.00KN/M-$0.859.9%
FY 2025
Q4 2025derivedDec 31, 2025Feb 23, 2026 · after-hoursFeb 23, 202654 d10-K$64.07M+417.8%—+28.0%
Q3 2025Sep 30, 2025Nov 5, 2025 · after-hoursNov 5, 202536 d10-Q$240.00K−89.9%-$1.175.4%
Q2 2025Jun 30, 2025Aug 6, 2025 · after-hoursAug 6, 202537 d10-Q$1.21M−60.5%-$0.8014.6%
Q1 2025Mar 31, 2025May 7, 2025 · after-hoursMay 8, 202538 d10-Q$3.03M−94.6%-$0.883.4%
FY 2024
Q4 2024derivedDec 31, 2024Feb 26, 2025 · after-hoursFeb 27, 202558 d10-K$12.37M−26.3%—11.9%
Q3 2024Sep 30, 2024Oct 31, 2024 · after-hoursNov 4, 202435 d10-Q$2.38M−9.8%-$1.56+23.8%
Q2 2024Jun 30, 2024Aug 1, 2024 · after-hoursAug 1, 202432 d10-Q$3.08M−19.0%-$1.025.3%
Q1 2024Mar 31, 2024May 2, 2024 · after-hoursMay 3, 202433 d10-Q$56.38M−10.5%-$0.48+18.9%
Earlier years, FY 2018 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 4, 2026070273
10-QAug 5, 2026053549
10-QMay 7, 2026031471
10-KFeb 23, 2026010749
10-QNov 5, 2025049694
10-QAug 6, 2025038431
10-QMay 8, 2025023291
10-KFeb 27, 2025008245
10-QNov 4, 2024044995
10-QAug 1, 2024034195

Provenance

ProvenanceData status and checks

Vir Biotechnology, Inc. · CIK 1706431 · Engraved from SEC EDGAR